About CMS

Current Location:About CMS > Business Introduction

Pharmaceutical Business


Innovative Research

With more than two decades experience in introduction of and investment in global products, CMS has accumulated extensive overseas channel resources and market reputation, and established a unique and systematic product evaluation system. The Group acquires innovative products and technologies through industrial equity investment in innovative R&D companies or strategic cooperation with leading pharmaceutical companies around the world. The Group has made equity investments in a number of R&D companies from the U.K., France, Switzerland, the U.S., China, etc., and initiated a new model for industrial investment in innovative drugs, achieving combination of complementary advantages and strong alliance to accelerate the R&D and commercialization progress of innovative products. As at 30 June 2021, the Group has more than 20 innovative products with relatively high innovation level, good market potential and competitive differentiation advantages; among them, 9 innovative products are approved for marketing in the U.S. and/or Europe, and the China’s registration clinical trials of 4 innovative products are completed or underway.

Capitalizing on its expert network covering a wide range of departments and its experienced clinical development teams, the Group strictly controls the core clinical processes such as clinical design, patient enrollment, quality control, etc. while cooperating with CROs, so as to achieve efficient and quality progress of clinical development of innovative drugs.


Professional Academic Promotion

The Group has proven experience in market access, academic promotion and government affairs in regard to prescription drugs for more than two decades, and has established a professional, compliant and efficient academic promotion system, with which the Group has built professional brand images and achieved good sales records for a number of quality branded drugs in China. Since 1998, the Group has started the campus recruitment for fresh graduates with bachelor or master degree in Medicine and Pharmacy, and has developed a systematic internal training system to establish a professional and compliant promotion team with strong execution; some professionals from the Group’s management team have medical working experience, understand the medication patterns of Chinese patients, and are able to develop precise product promotion strategies and efficiently implement the strategies.

As at 31 December 2020, Group’s academic promotion network has covered approximately 57,000 hospitals and medical institutions with around 3,300 academic promotion staff in China.


Pharmaceutical Manufacturing

The Group’s imported products are produced by entrusted overseas pharmaceutical manufacturers, while some of the domestic products are produced by the Group’s manufacturing plants. The Group has more than two decades of experience in pharmaceutical manufacturing, and has pharmaceutical manufacturing sites in Hunan, Hebei and Shenzhen, which occupy a total area of approximately 110,000 square meters, and owns Pharmaceutical Production Licenses for various dosage forms and Production Permits for imported drugs sub-packaging. The Group’s rich production experiences as well as its mature quality control system have laid an important foundation for localized preparation manufacturing of some overseas innovative products in China.



Dermatology and Medical Aesthetic Business


CMS has been deeply engaged in the field of skin health for many years, and has deployed a number of dermatology products with competitive differentiation advantages, such as Hirudoid (existing exclusive product), Tildrakizumab (innovative drug at the registration trial stage in China); meanwhile, the Group has accumulated abundant sales and promotion resources in the dermatology field. As at 31 December 2020, the Group's sales and promotion network has covered about 57,000 hospitals and medical institutions, over 200,000 retail pharmacies, and about 12,000 dermatologists, and has approximately 700 professional dermatology promotion staff. In order to effectively utilize the sales and promotion channel resources and improve the efficiency in the dermatology field, the Group acquired Luqa Ventures (Luqa), a dermatology specialty company, on 1 February 2021, which has enriched the Group’s dermatology line and expanded the Group’s business boundary with its strengths to enter the medical aesthetic field.

The Group will continuously utilize its domestic and overseas channel resources to deploy professional dermatological products and cutting-edge medical aesthetic solutions globally to build a comprehensive skin health product matrix consisting of prescription medicines, medical devices, medical aesthetic solutions and dermatology-grade skin care products; in the meantime, the Group will leverage its extensive network resources in the dermatology, and integrate channels such as hospitals, retail pharmacies, e-commerce, medical aesthetic institutions, and distributors to build a leading skin management and high-end medical aesthetic brand in China with first-rate competitiveness, in order to fulfill the increasingly diverse needs for skin management and beauty of Chinese consumers.



Healthcare Business


Capitalizing on its strengths such as overseas channel resources accumulated for more than two decades, good reputation, unique product evaluation system, responsive global supply chain system, and strong promotion network, CMS stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, and supplies the products to Mainland China through cross-border e-commerce platforms, so as to provide consumers with healthy lives.

"CMS Health Overseas Flagship Stores" has been officially launched on Youzan, JD and Tmall platforms. The flagship stores offer a full range of products that meet the all-round health care needs of people at different ages.